85278-58-6

Upstream product

• 85277-86-7 (E)-2-(3,4-dimethoxyphenyl)-3-fluoroprop-2-en-1-ol 
• 85277-70-9 ethyl 2-(tert-butoxycarbonyl)-2-(difluoromethyl)-2-(3,4-dimethoxyphenyl)acetate 
• 85277-60-7 ethyl 2-(tert-butoxycarbonyl)-2-(3,4-dimethoxyphenyl)acetate 
• 85277-77-6 (E)-ethyl 2-(3,4-dimethoxyphenyl)-3-fluoroacrylate 
• 13790-42-6 tert-butyl 3,4-dimethoxyphenylacetate 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 

Downstream Products

• 85278-66-6 (E)-2-(3',4'-dimethoxyphenyl)-3-fluoroallylamine 
• 85277-95-8 (E)-1-fluoro-2-(3,4-dimethoxyphenyl)-3-phthalimidopropene 

Relevant academic research and scientific papers

NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.